0000939767-19-000141.txt : 20190619
0000939767-19-000141.hdr.sgml : 20190619
20190619213012
ACCESSION NUMBER: 0000939767-19-000141
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190617
FILED AS OF DATE: 20190619
DATE AS OF CHANGE: 20190619
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lamb Peter
CENTRAL INDEX KEY: 0001387306
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 19907349
MAIL ADDRESS:
STREET 1: PO BOX 511, 170 HARBOR WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94083-0511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0103
BUSINESS ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wf-form4_156099419666093.xml
FORM 4
X0306
4
2019-06-17
0
0000939767
EXELIXIS, INC.
EXEL
0001387306
Lamb Peter
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY
ALAMEDA
CA
94502
0
1
0
0
EVP, Scientific Strategy & CSO
Common Stock
2019-06-17
4
M
0
95404
5.56
A
212601
D
Common Stock
2019-06-17
4
M
0
4596
1.70
A
217197
D
Common Stock
2019-06-17
4
S
0
100000
20.49
D
117197
D
Common Stock
2019-06-18
4
M
0
75404
1.70
A
192601
D
Common Stock
2019-06-18
4
M
0
24596
5.51
A
217197
D
Common Stock
2019-06-18
4
S
0
100000
20.67
D
117197
D
Common Stock
2019-06-19
4
M
0
17404
5.51
A
134601
D
Common Stock
2019-06-17
4
S
0
17404
20.76
D
117197
D
Common Stock
17105
I
By 401(k)
Option (right to buy)
5.56
2019-06-17
4
M
0
95404
0
A
2013-09-21
2019-09-20
Common Stock
95404.0
0
D
Option (right to buy)
1.7
2019-06-17
4
M
0
4596
0
A
2015-07-20
2021-09-18
Common Stock
4596.0
395404
D
Option (right to buy)
1.7
2019-06-18
4
M
0
75404
0
A
2015-07-20
2021-09-18
Common Stock
75404.0
320000
D
Option (right to buy)
5.51
2019-06-18
4
M
0
24596
0
A
2015-07-20
2020-09-17
Common Stock
24596.0
17404
D
Option (right to buy)
5.51
2019-06-19
4
M
0
17404
0
A
2015-07-20
2020-09-17
Common Stock
17404.0
0
D
Includes 49,374 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.29 to $20.69. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.42 to $20.87. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.59 to $20.91. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of June 17, 2019.
The option, representing the right to purchase a total of 123,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016.
The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.
On September 18, 2013, the Reporting Person was granted a performance-based stock option to purchase 84,000 shares of common stock under the Exelixis, Inc. 2011 Equity Incentive Plan. Vesting of the option is tied to performance goals set by the Compensation Committee ("Committee") as follows: (i) 50% of the option will vest if the Committee determines that top-line efficacy data received from the METEOR Phase 3 clinical trial of cabozantinib in metastatic renal cell carcinoma met its primary endpoint at a specified level, which the Committee determined had been achieved on July 20, 2015, resulting in the vesting of 50% of the option; and (ii) 50% of the option will vest if the Committee confirms the approval of cabozantinib by the U.S. Food and Drug Administration or European Medicines Agency for the treatment of metastatic castration-resistant prostate cancer, which the Committee determined could not be achieved on December 10, 2014, resulting in the forfeiture of 50% of the option.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
2019-06-19